What is NDC 51759-208?

51759-208 is the product NDC for Epysqli (eculizumab-aagh), Eculizumab 300 mg/30mL injection, solution, listed with the FDA by Teva Pharmaceuticals USA, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Teva Pharmaceuticals USA, Inc., NDC labeler code 51759. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Epysqli?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Epysqli NDC 51759-208 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)51759-208Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51759-0208Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51759-208-13	51759020813	1 VIAL, SINGLE-DOSE in 1 CARTON (51759-208-13) / 30 mL in 1 VIAL, SINGLE-DOSEMarketed from Apr 7, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Epysqli
Generic name (nonproprietary): eculizumab-aagh
Active ingredients: Eculizumab — 300 mg/30mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Teva Pharmaceuticals USA, Inc.NDC labeler code 51759
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761340
Marketing start: Apr 7, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Complement Inhibitors (Mechanism)
Identifiers: Product ID 51759-208_4898d7e0-c6d4-4fd7-8da2-b122296521eaSPL ID 4898d7e0-c6d4-4fd7-8da2-b122296521eaSPL set ID 1fa1aa80-1c59-44d4-9841-b6c52882651bRxCUI 2706338, 2706345UNII A3ULP0F556
Pharmacologic class: Complement Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451759020813 followed by a unit qualifier and the quantity

Package 51759-0208-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

EPYSQLI is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use EPYSQLI is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody p…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 51759-208

What is NDC 51759-208?: 51759-208 is the product NDC for Epysqli (eculizumab-aagh), Eculizumab 300 mg/30mL injection, solution, listed with the FDA by Teva Pharmaceuticals USA, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Epysqli (Eculizumab-aagh).
What is the active ingredient?: Eculizumab.
Who is the labeler?: Teva Pharmaceuticals USA, Inc., NDC labeler code 51759. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Epysqli?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Epysqli (Eculizumab-aagh) NDC 51759-208